Back Lipiodol Spanish Huile éthiodée French ヨード化ケシ油脂肪酸エチルエステル Japanese 리피오돌 Korean Йодолипол Russian Lipiodol Serbo-Croatian Lipiodol Serbian Lipiodol Vietnamese
| Clinical data | |
|---|---|
| Trade names | Lipiodol, Ethiodol, Vividol |
| Other names | ethiodized oil, ethyl esters of iodised fatty acids |
| AHFS/Drugs.com | International Drug Names |
| License data | |
| Routes of administration | by mouth, injection (IM, intralymphatic, intrauterine, selective hepatic intra-arterial) |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| ECHA InfoCard | 100.122.502 |
Iodized oil, also known as ethiodized oil, brand name Lipiodol, is a medication derived from poppyseed oil and iodine. When given by injection, it is a radio-opaque contrast agent that is used to outline structures in radiological investigations.[1][2] When given orally or by intramuscular injection once or twice a year, it prevents endemic goitre in remote communities.[3] It has an additional use in gastric variceal obliteration as a dilutant that does not affect polymerization of cyanoacrylate.
When used as tissue contrast, iodized oil has a risk of entering the vein and causing embolism in the brain and lungs.[4] There is a boxed warning referring to the risk of embolism.[5] Use as iodine supplementation is recommended in regions where deficiency is common, otherwise it is not recommended.[3] It should not be used for hysterosalpingography in pregnancy.[5]
Iodized oil was first made in 1901 by Marcel Guerbet and Laurent Lafay. Originally used to treat iodine deficiency, it was identified as an effective radiocontrast in 1921 by Sicard and Forestier, before returning as a tool to treat iodine deficiency in goiter eradication campaigns of the 1980s.[6] Under the name "iodine", iodized oil is on the World Health Organization's List of Essential Medicines, in liquid and capsule form.[3][7]
- ^ Ahrar K, Gupta S (January 2003). "Hepatic artery embolization for hepatocellular carcinoma: technique, patient selection, and outcomes". Surgical Oncology Clinics of North America. 12 (1): 105–126. doi:10.1016/s1055-3207(02)00089-3. PMID 12735133.
- ^ Sato T (April 2002). "Locoregional immuno(bio)therapy for liver metastases". Seminars in Oncology. 29 (2): 160–167. doi:10.1053/sonc.2002.31716. PMID 11951214.
- ^ a b c World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 499. hdl:10665/44053. ISBN 9789241547659.
- ^ Gomi T, Hasegawa M (2012). "Radiological contrast agents and radiopharmaceuticals". Side Effects of Drugs Annual. 34: 749–760. doi:10.1016/b978-0-444-59499-0.00046-5. ISBN 978-0-444-59499-0.
- ^ a b "DailyMed - LIPIODOL- ethiodized oil injection". dailymed.nlm.nih.gov.
- ^ Bonnemain B, Guerbet M (1995). "Histoire du Lipiodol (1901-1994) ou Comment un médicament peut évoluer avec son temps" [The history of Lipiodol (1901-1994) or How a medication may evolve with the times]. Revue d'Histoire de la Pharmacie (in French). 42 (305): 159–170. doi:10.3406/pharm.1995.4238. PMID 11640460.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.